Novation MedTech Completes Tens of Millions of RMB Angel Round to Accelerate Development of Its China-First AI-Powered Energy Platform for Diagnosis and Therapy

Novation MedTech today announced that it has successfully completed several tens of millions of RMB Angel round financing. This round was led by Vision Knight Purple Bull Fund, a well-known investment institution focused on the healthcare and technology sectors, with participation from Dandelion Fund, Hengqin Hongquan Investment, and several industry veterans. The proceeds will accelerate the product development, clinical trials, and regulatory registration of its China-first AI-driven acoustic energy platform, aiming to create a brand-new, technology-driven ecosystem in the professional consumer healthcare space.

Since its establishment, Novation MedTech has been committed to becoming a global leader in the field of non-invasive, non-metabolic interventional precision medicine. The company's core innovation, the "AI-Powered Acoustic Energy Platform," deeply integrates high-precision ultrasound imaging technology, an advanced AI-assisted diagnostic system, and a China-first novel energy platform. This platform is designed to establish an intelligent, closed-loop management system covering the entire "diagnosis-assessment-treatment-follow-up" process, fundamentally improving the precision and standardization of consumer-grade medical products, effectively reducing over-reliance on physicians' individual experience, and delivering a revolutionary technological solution to the industry.

As a China-first novel energy technology platform, Novation MedTech's products feature significant advantages: non-invasive, multi-layered, programmable, and capable of precise, immediate sculpting. Through efficient pre-procedural energy mapping simulation, precise intra-procedural energy delivery, and quantitative post-procedural effect tracking, the platform offers patients a full-cycle, safe, efficient, and highly personalized skin rejuvenation and body contouring solution. Furthermore, leveraging its powerful AI technology and integrated diagnostic and therapeutic platform, the company is actively expanding into areas including safe and effective home-use acoustic energy products, a sports rehabilitation intervention platform, and consumer neuromodulation applications.

The lead investor in this round, Vision Knight Purple Bull Fund, was jointly established in 2026 by Vision Knight Capital and Purple Bull Startups, focusing on early-stage healthcare companies. This fund leverages Purple Bull Startups' professional expertise and industry resources in healthcare investment, combined with Vision Knight Capital's extensive investment experience in consumer, technology, and cross-border sectors and its unique consulting-empowered strategy. It seeks to deeply explore sustainable commercial value driven by emerging scenarios and innovative technologies, with primary investments in frontier areas such as innovative medical devices and advanced biotechnology.

Currently, Novation MedTech's first product has entered registered clinical trials. The company plans to fully initiate the NMPA Class III medical device registration clinical trial for its novel energy platform in 2026, while simultaneously advancing certification processes with the FDA and other overseas markets, actively pursuing a global market presence.